KROS Q4 2022 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$32M

Net Income

-$30M

EPS (Diluted)

$-1.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$307M

Total Liabilities

$29M

Stockholders' Equity

$277M

Cash & Equivalents

$279M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$20M	-100.0%
Gross Profit	$0	$20M	-100.0%
Operating Income	-$32M	-$5M	-556.8%
Net Income	-$30M	-$7M	-328.2%